Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 7
Submit an article Journal homepage
2,384
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy

Jakob Nikolas KatherDepartment of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany;Heidelberg Site, German Cancer Consortium (DKTK), Heidelberg, Germany;Clinical Cooperation Unit Applied Tumor Immunity, D120, German Cancer Research Center (DKFZ), Heidelberg, GermanyORCID Iconhttp://orcid.org/0000-0002-3730-5348 http://orcid.org/0000-0002-3730-5348 http://orcid.org/0000-0002-3730-5348
ORCID Icon ORCID Icon ORCID Icon,
Anna Sophie BerghoffDepartment of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany;Clinical Unit for Experimental Oncology Therapy, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
,
Dyke FerberDepartment of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany;Clinical Cooperation Unit Applied Tumor Immunity, D120, German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Meggy Suarez-CarmonaDepartment of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany;Clinical Cooperation Unit Applied Tumor Immunity, D120, German Cancer Research Center (DKFZ), Heidelberg, GermanyORCID Iconhttp://orcid.org/0000-0002-8892-1546
ORCID Icon,
Constantino Carlos Reyes-AldasoroDepartment of Electrical and Electronic Engineering, School of Mathematics, Computer Science and Engineering, City, University of London, London, UK
,
Nektarios A. ValousDepartment of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany;Clinical Cooperation Unit Applied Tumor Immunity, D120, German Cancer Research Center (DKFZ), Heidelberg, GermanyORCID Iconhttp://orcid.org/0000-0002-4014-2404
ORCID Icon,
Rodrigo Rojas-MoraledaDepartment of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany;Clinical Cooperation Unit Applied Tumor Immunity, D120, German Cancer Research Center (DKFZ), Heidelberg, Germany
,
Dirk JägerDepartment of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany;Heidelberg Site, German Cancer Consortium (DKTK), Heidelberg, Germany;Clinical Cooperation Unit Applied Tumor Immunity, D120, German Cancer Research Center (DKFZ), Heidelberg, Germany
&
Niels HalamaDepartment of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany;Heidelberg Site, German Cancer Consortium (DKTK), Heidelberg, Germany;Clinical Cooperation Unit Applied Tumor Immunity, D120, German Cancer Research Center (DKFZ), Heidelberg, GermanyCorrespondence[email protected]
 show all
Article: e1444412 | Received 29 Jan 2018, Accepted 16 Feb 2018, Published online: 29 Mar 2018

References

  • Yang Y. Cancer immunotherapy: Harnessing the immune system to battle cancer. J Clin Invest. 2015;125:3335–7. doi:10.1172/JCI83871. PMID:26325031.
  • Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. doi:10.1056/NEJMoa1003466. PMID:20525992.
  • Jager D, Halama N, Zornig I, Klug P, Krauss J, Haag GM. Immunotherapy of Colorectal Cancer. Oncol Res Treat. 2016;39:346–50. doi:10.1159/000446713. PMID:27259331.
  • Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5:12472–508. doi:10.18632/oncotarget.2998. PMID:25537519.
  • Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic Viruses in Cancer Treatment: A Review. JAMA Oncol. 2017;3:841–849. doi:10.1001/jamaoncol.2016.2064.
  • Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35–45. doi:10.1038/nrc971. PMID:12509765.
  • Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003;21:2415–32. doi:10.1200/JCO.2003.06.041. PMID:12805342.
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64. doi:10.1038/nrc3239. PMID:22437870.
  • Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33:1974–82. doi:10.1200/JCO.2014.59.4358. PMID:25605845.
  • Kammertoens T, Schuler T, Blankenstein T. Immunotherapy: target the stroma to hit the tumor. Trends Mol Med. 2005;11:225–31. doi:10.1016/j.molmed.2005.03.002. PMID:15882610.
  • Busch S, Andersson D, Bom E, Walsh C, Stahlberg A, Landberg G. Cellular organization and molecular differentiation model of breast cancer-associated fibroblasts. Mol Cancer. 2017;16:73. doi:10.1186/s12943-017-0642-7. PMID:28372546.
  • Villanueva MT. Immunotherapy: T cells get a ride. Nat Rev Cancer. 2017;17:333. doi:10.1038/nrc.2017.39. PMID:28536454.
  • Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999;10:281–7. doi:10.1016/S1074-7613(00)80028-X. PMID:10204484.
  • Yarchoan M, Johnson BA, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017;17:209–22. doi:10.1038/nrc.2016.154. PMID:28233802.
  • Roy S, Trinchieri G. Microbiota: A key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17:271–85. doi:10.1038/nrc.2017.13. PMID:28303904.
  • Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016;16:121–6. doi:10.1038/nrc.2016.2. PMID:26822578.
  • Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16:447–62. doi:10.1038/nrc.2016.54. PMID:27339708.
  • Gammaitoni L, Leuci V, Mesiano G, Giraudo L, Todorovic M, Carnevale-Schianca F, Aglietta M, Sangiolo D. Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. Expert Opin Biol Ther. 2014;14:1259–70. doi:10.1517/14712598.2014.918099. PMID:24835841.
  • Prachayasittikul V, Prathipati P, Pratiwi R, Phanus-Umporn C, Malik AA, Schaduangrat N, Seenprachawong K, Wongchitrat P, Supokawej A, Prachayasittikul V, et al. Exploring the epigenetic drug discovery landscape. Expert Opin Drug Discov. 2017;12:345–62. doi:10.1080/17460441.2017.1295954. PMID:28276705.
  • Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11:109–24. doi:10.1038/nrd3627. PMID:22293567.
  • Pan H, Chen L, Xu Y, Han W, Lou F, Fei W, Liu S, Jing Z, Sui X. Autophagy-associated immune responses and cancer immunotherapy. Oncotarget. 2016;7:21235–46. PMID:26788909.
  • Cairns RA, Mak TW. The current state of cancer metabolism. Nat Rev Cancer. 2016;16:613–4. doi:10.1038/nrc.2016.100.
  • Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372–7. doi:10.1073/pnas.1533209100. PMID:12826605.
  • Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100:4712–7. doi:10.1073/pnas.0830997100. PMID:12682289.
  • Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800. doi:10.1038/nm730. PMID:12091876.
  • Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75. doi:10.1200/JCO.2009.26.7609. PMID:20516446.
  • Reyes-Aldasoro CC. The proportion of cancer-related entries in PubMed has increased considerably; is cancer truly “The Emperor of All Maladies”? PLoS One. 2017;12:e0173671. doi:10.1371/journal.pone.0173671. PMID:28282418.
  • Harrower M, Brewer CA. ColorBrewer.org: an online tool for selecting colour schemes for maps. Cartogr J. 2003;40:27–37. doi:10.1179/000870403235002042.
  • Woolf SH. The meaning of translational research and why it matters. JAMA. 2008;299:211–3. doi:10.1001/jama.2007.26. PMID:18182604.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.